Zylet and Weakness - a phase IV clinical study of FDA data

Summary:

Weakness is reported as a side effect among people who take Zylet (loteprednol etabonate; tobramycin), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Singulair, and have Asthma.

The phase IV clinical study analyzes which people have Weakness when taking Zylet. It is created by eHealthMe based on reports of 485 people who have side effects when taking Zylet from the FDA, and is updated regularly.

What is Zylet?

Zylet has active ingredients of loteprednol etabonate; tobramycin. eHealthMe is studying from 493 Zylet users. Check the latest studies of Zylet.

What is Weakness?

Weakness is found to be associated with 3,632 drugs and 6,557 conditions by eHealthMe. Check the latest studies of Weakness.

On Sep, 21, 2025

485 people reported to have side effects when taking Zylet.
Among them, 17 people (3.51%) have Weakness.

Among these 17 people:

How long have people been on Zylet when they have Weakness? *

What is the gender of people who have Weakness when taking Zylet? *

female: 82.35 %
male: 17.65 %

What is the age of people who have Weakness when taking Zylet? *

What are other drugs people take besides Zylet? *

What are other side effects people have besides Weakness? *

Rashes (redness): 9 people, 52.94%
Swelling: 9 people, 52.94%
Dyspnea (difficult or laboured breathing): 9 people, 52.94%
Staphylococcal Scalded Skin Syndrome (the staphylococcal bacteria produce a poison that causes the skin damage): 8 people, 47.06%
Oedema Peripheral (superficial swelling): 8 people, 47.06%
Localised Infection (infection at the single location): 8 people, 47.06%
Hair Loss: 8 people, 47.06%
Psoriasis (immune-mediated disease that affects the skin): 8 people, 47.06%
Rash Pruritic (redness with itching): 8 people, 47.06%
Skin Exfoliation (removal of the oldest dead skin cells): 8 people, 47.06%

What are the existing conditions these people have? *

Asthma: 9 people, 52.94%
Sinusitis (inflammation of sinus): 8 people, 47.06%
Diabetes: 8 people, 47.06%
Rashes (redness): 8 people, 47.06%
Nervousness: 8 people, 47.06%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 8 people, 47.06%
Itching: 8 people, 47.06%
Gastric Disorder (disease of stomach): 8 people, 47.06%
Prostate Cancer Stage 0: 3 people, 17.65%
Pneumonia: 3 people, 17.65%

* Approximation only. Some reports may have incomplete information.

Do you take Zylet and have Weakness?

- Check whether Weakness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zylet:

Zylet (493 reports)

Weakness treatments and more:

Weakness (586,860 reports)

How severe was Weakness and when was it recovered:

Weakness in Zylet

Expand to all the drugs that have ingredients of loteprednol etabonate; tobramycin:

Weakness and drugs with ingredients of loteprednol etabonate; tobramycin (17 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Zylet:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weakness:

Weakness (3,632 drugs)

Browse all the conditions that are associated with Weakness:

Weakness (6,557 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on loteprednol etabonate; tobramycin (the active ingredients of Zylet) and Zylet (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.